3E Bioventures portfolio company Biosion recently shared the results from the ADAMANT study, a phase 2 proof-of-concept trial in AD subjects treated with Bosakitug, a high potency anti-TSLP mAb, in a podium presentation at the Revolutionizing Atopic Dermatitis conference in Chicago, IL. “Despite the limitations of the POC trial being open label, with a limited sample size of 21 subjects, the response profile is truly remarkable. We knew we had created an antibody with very high potency due to its long residency time on TSLP that could neutralize and clear TSLP from deep tissue spaces effectively. These promising clinical data give us a great deal of confidence to conduct a randomized and controlled phase 2 trial in moderate to severe AD as well as other indications,” said Biosion Chief Development Officer Hugh Davis, PhD.
Biosion Today Presented Key Phase 2 POC Clinical Study Results for Bosakitug, an Anti-TSLP mAb, in Atopic Dermatitis Subjects at the Revolutionizing Atopic Dermatitis Conference. We are excited to see that Bosakitug's efficacy will lead to new therapeutic options for patients! #antibody #TSLP #AtopicDermatitis
